RxDoctor Payments Data

Mathew Castelino, MD

Psychiatry · Gary, INNPI 1912970229

Payments from drug & device makers

$5,194in general payments, 2019–2025

Across 300 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$643
  • Teva Pharmaceuticals USA, Inc.$622
  • Vanda Pharmaceuticals Inc.$619
  • Otsuka America Pharmaceutical, Inc.$582
  • Alkermes, Inc.$540
  • Lundbeck LLC$513
  • plus $2K from 8 others

What the payments were for

  • Food & beverage$4,99596%
  • Education$1994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,194 in reported general payments places this provider in the 85th percentile of 514 psychiatry providers in Indiana.

See all psychiatry providers in Indiana

Medicare billing

Part B allowed, 2024
$13,105
Medicare patients
57
Services billed
260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine103$648,685
Invega SustennaPaliperidone Palmitate177$554,486
Abilify MaintenaAripiprazole88$255,504
FanaptIloperidone67$220,961
CaplytaLumateperone Tosylate125$214,814
RexultiBrexpiprazole117$198,393
VraylarCariprazine Hcl131$196,002
AustedoDeutetrabenazine35$118,002
Abilify AsimtufiiAripiprazole14$79,968
PerserisRisperidone21$63,495
UzedyRisperidone14$49,014
AristadaAripiprazole Lauroxil12$45,683
Lurasidone Hcl131$42,654
SecuadoAsenapine26$37,243
LybalviOlanzapine/Samidorphan Malate24$36,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy$622$815,702152 claims
Johnson & JohnsonInvega Sustenna$643$554,486177 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti, Abilify Asimtufii$582$533,865219 claims
Vanda Pharmaceuticals Inc.Fanapt$619$220,96167 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$108$214,814125 claims
AbbVieVraylar$432$196,002131 claims
Alkermes, Inc.Aristada, Lybalvi$540$82,62136 claims
Indivior Inc.Perseris$217$63,49521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 514 psychiatry providers in Indiana.

Other psychiatry in Gary

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →